Danvilostomig vs Volrustomig

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 x CTLA-4 · full Non-Small Cell Lung Cancer pipeline

Danvilostomig

Developed by Sichuan Baili Pharmaceutical

Phase 2 in Non-Small Cell Lung Cancerbispecific antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT05949606 (registry estimate)

No aligned efficacy figure on record for this race.

Volrustomig

Developed by AstraZeneca

Phase 3 in Non-Small Cell Lung Cancerbispecific antibody
Partial signal

NCT05984277 · Phase 3 · active, not recruiting

eVOLVE-Lung02 was a randomized, open-label Phase 3 in 895 participants with metastatic non-small cell lung cancer with progression-free and overall survival as dual primary endpoints. An independent committee judged at an interim review that neither endpoint was likely to be met, and the sponsor stopped the trial. A randomized but open-label trial with a negative result is moderate evidence of no benefit.

Next expected readout: June 2027 · NCT04686305 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) (using BICR assessments according to RECIST 1.1) (Up to approximately 6 years); Overall Survival (OS), in PD-L1-negative participants. (Up to approximately 6 years): Dual primary endpoints (PFS and OS) not expected to be met: the IDMC concluded the volrustomig combination was unlikely to meet either, and AstraZeneca is discontinuing the trial (2026-08-17). (missed)

Result source: NCT05984277

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDanvilostomigVolrustomig
PFS, median—Not reported—Trial running · NCT05984277
OS, median—Not reported—Trial running · NCT05984277
ORR—Not reported—Trial running · NCT05984277
Duration of response, median—Not reported—Trial running · NCT05984277

PFS, median

Danvilostomig
—Not reported
Volrustomig
—Trial running · NCT05984277

OS, median

Danvilostomig
—Not reported
Volrustomig
—Trial running · NCT05984277

ORR

Danvilostomig
—Not reported
Volrustomig
—Trial running · NCT05984277

Duration of response, median

Danvilostomig
—Not reported
Volrustomig
—Trial running · NCT05984277
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Danvilostomig: no structured comparison results are available for Non-Small Cell Lung Cancer.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Volrustomig
Dual primary endpoints (PFS and OS) not expected to be met: the IDMC concluded the volrustomig combination was unlikely to meet either, and AstraZeneca is discontinuing the trial (2026-08-17). NCT05984277 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Danvilostomig's landscape · Volrustomig's landscape